Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

Авторы
Chi K.N. 1 , Gleave M. 1 , Higano C.S. 2 , Blumenstein B. 3 , Ferrero J.M. 4 , Reeves J. 5 , Feyerabend S. 6 , Stenzl A. 7 , Gravis G. 8 , Merseburger A.S. 9 , Bergman A.M. 10 , Mukherjee S.D. 11 , Zalewski P. 12 , Saad F. 13 , Jacobs C. 14 , De Bono J.S. 15
Журнал
The Lancet Oncology
Номер выпуска
4
Язык
Английский
Страницы
473-485
Статус
Опубликовано
Том
18
Год
2017
Организации
  • 1 Department of Medicine|Division of Medical Oncology|University of British Columbia|BC Cancer Agency|Vancouver Prostate Centre
  • 2 Department of Medicine|Division of Medical Oncology|University of Washington|Fred Hutchinson Cancer Research Center
  • 3 Trial Architecture Consulting
  • 4 Centre Antoine Lacassagne
  • 5 Florida Cancer Specialists
  • 6 Department of Urology
  • 7 University of Tübingen
  • 8 Institut Paoli Calmette|Department of Cancer Medicine
  • 9 Department of Urology|University Hospital Schleswig-Holstein
  • 10 Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital
  • 11 Juravinski Cancer Centre at Hamilton Health Sciences
  • 12 Durham Regional Cancer Centre
  • 13 Centre Hospitalier de l'Université de Montréal
  • 14 OncoGenex Pharmaceuticals
  • 15 Drug Development Unit|Royal Marsden Hospital and Institute of Cancer Research
Цитировать
ГОСТ MLA RIS BibTex
Поделиться

Другие записи